Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis

Yin, Juan Juan; Chen, Yangyang; Li, Yang; Wang, Chaoyang; Zhang, Qizhou

doi:10.1016/j.ijid.2022.10.005

Cited by 27 publications

(22 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A review of 22 studies with 6522 PWH demonstrates that, after the second dose, seroconversion in PWH was slightly lower than that in healthy individuals [5]. The trend to lower immune responses in PWH cohorts compared with HIV-negative populations are in line with reports on other vaccines, for example, against influenza or hepatitis B virus [6].…”

supporting

confidence: 57%

Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals

Vanham

2023

Aids

View full text Add to dashboard Cite

supporting

confidence: 57%

Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals

Vanham

2023

Aids

View full text Add to dashboard Cite

“…The results of the above-mentioned studies correspond with the results of three meta-analyses [26 ▪ ,27,28]. In the first meta-analysis, a total of 34 eligible studies covering 4517 PLWH were included.…”

Section: Safety and Immunogenicity Of Covid 19 Vaccines In People Liv...mentioning

confidence: 56%

The effect of HIV on COVID-19 vaccine responses

Levy

Rahav

2023

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

Purpose of reviewPersons living with HIV (PLWH) may have a moderately increased risk of morbidity and mortality from COVID-19 infection, especially if viral load is not controlled and if they are immunosuppressed. Vaccination against SARS-CoV-2 is the most effective measure to prevent morbidity and mortality. However, individuals with HIV/AIDS may have less protection after vaccination. The purpose of this review is to summarize some of the recent studies focused on examining the safety, immunogenicity and effectiveness of anti-SARS-CoV-2 vaccines.Recent findingsThe safety of all anti-SARS-CoV-2 vaccines among PLWH is not different from the safety of these vaccines among HIV-negative individuals and is acceptable. PLWH with viral suppression and immune reconstitution (CD4+ cell count > 350 cells/μl) may reach almost same immunogenicity such as people without HIV albeit antibody levels and neutralization may decline more rapidly than in people without HIV. PLWH with viremia or immunosuppressed, especially AIDS, have less immunogenicity.SummaryFull vaccination against SARS-CoV-2 is a well tolerated and efficient way to prevent mortality and morbidity from COVID-19 among PLWH and AIDS patients. It is very important to follow recommended booster vaccination for a continuous and prompt immunogenicity.

show abstract

“…Up to date, more than 20 clinical trials regarding COVID-19 vaccines in PLWH have been registered on ClinicalTrials.gov (12). In general, these studies have demonstrated favorable immunogenicity and efficacy of COVID-19 vaccines (13)(14)(15)(16)(17). However, few studies published data on the safety and immunogenicity of inactivated vaccines in PLWH.…”

Section: Introductionmentioning

confidence: 99%

The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study

et al. 2023

View full text Add to dashboard Cite

BackgroundPeople living with HIV (PLWH) are more vulnerable to SARS-CoV-2. However, evidence on the immunogenicity of coronavirus disease 2019 (COVID-19) vaccines in this population is insufficient. The objective of this study is to assess the immunogenicity and safety of the two-dose schedule of Sinovac CoronaVac for 6 months postvaccination in PLWH.MethodsWe conducted a multicenter prospective cohort study among PLWH and HIV-negative adults in China. Participants who received two doses of CoronaVac prior to the recruitment were allocated into two groups and followed up for 6 months. The neutralizing antibodies (nAbs), immunoglobulin G against the receptor-binding domain of the spike protein (S-IgG), and gamma-interferon (IFN-γ) were measured to assess the associations among CoronaVac immunogenicity and related factors. Adverse reactions were collected to evaluate the safety profile of vaccination.ResultsA total of 203 PLWH and 100 HIV-negative individuals were enrolled. A small portion of participants reported mild or moderate adverse reactions without serious adverse events. Median nAbs level in PLWH (31.96 IU/mL, IQR: 12.34-76.40) was lower than that in the control group (46.52 IU/mL, IQR: 29.08-77.30) at the 2-4 weeks postvaccination (P=0.002), and the same trend was presented for median S-IgG titer (37.09 vs. 60.02 IU/ml) (both P <0.05). The nAbs seroconversion rate in the PLWH group was also lower than in the control group (75.86% vs. 89.00%). After then, the immune responses reduced over time in term of only 23.04% of PLWH and 36.00% of HIV-negative individuals had a positive seroconversion for nAbs at 6-month. The multivariable generalized estimating equation analysis showed that PLWH with CD4+T count≥350 cells/µL presented higher immune response than PLWH with CD4+T count <350 cells/µL in terms of antibody seroconversion and titers. The immunogenicity did not differ in participants with low or high HIV viral load. The S-antigen specific IFN-γ immunity was generally stable and had a slow attenuation in both two groups for 6 months postvaccination.ConclusionThe Sinovac CoronaVac was generally safe and immunogenic in PLWH, but the immunity response was inferior and the antibodies vanished faster compared to HIV-negative individuals. This study suggested a shorter than 6-month interval of prime-boost vaccination for PLWH to ensure a better protection.

show abstract

Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis

Cited by 27 publications

References 76 publications

Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals

Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals

The effect of HIV on COVID-19 vaccine responses

The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study

Contact Info

Product

Resources

About